INDV - Indivior Pharmaceuticals Inc
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $0.65
|
Rev Est: $305.6M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$43.75
DETAILS
HIGH:
$50.00
LOW:
$36.00
MEDIAN:
$44.50
CONSENSUS:
$43.75
UPSIDE:
32.34%
Market Cap:
4.12B
Volume:
1,007,587
Avg Volume:
2,315,411
52 Week Range:
7.62-38
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
1.14
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,030
IPO Date:
2014-12-29
EPS (TTM):
0.02
P/E Ratio:
820.38
Revenue (TTM):
1.19B
Total Assets:
1.32B
Total Debt:
375.00M
Cash & Equiv:
319.00M
Rev Growth (5Y):
8.6%
EPS Growth (5Y):
-56.3%
FCF Growth (5Y):
-45.4%
ROCE:
14.5%
Debt/Equity:
-1.08
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-10-30 | $0.72 | $0.38 | +89.5% | $314.0M | $306.2M | +2.5% |
| 2025-07-31 | $0.51 | $0.26 | +96.2% | $302.0M | $255.2M | +18.3% |
| 2025-04-24 | $0.41 | $0.22 | +86.4% | $266.0M | $242.3M | +9.8% |
| 2025-02-20 | $0.32 | $0.32 | 0.0% | $299.0M | $240.1M | +24.5% |
| 2024-10-24 | $0.54 | $0.31 | +74.2% | $307.0M | $260.4M | +17.9% |
| 2024-07-25 | $0.44 | $0.40 | +10.0% | $299.6M | $289.4M | +3.5% |
| 2024-04-25 | $0.37 | $0.42 | -11.9% | $282.7M | $299.8M | -5.7% |
| 2024-02-22 | $0.43 | $0.28 | +53.6% | $300.7M | $276.0M | +8.9% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.19B | 1.09B | 901.00M | 791.00M | 647.00M | 785.00M | 959.92M | 1.15B | 968.89M |
| Net Income | 2.00M | (129.00M) | (44.00M) | 205.00M | (148.00M) | 134.00M | 262.67M | 60.92M | 32.05M |
| EPS | 0.02 | 0.01 | -0.37 | 1.38 | -1.08 | 0.95 | 1.81 | 0.42 | 0.22 |
| Total Assets | 1.32B | 1.76B | 1.78B | 1.83B | 1.53B | 1.65B | 1.55B | 1.44B | 1.21B |
| Total Debt | 375.00M | 283.00M | 277.00M | 286.00M | 285.00M | 293.00M | 241.00M | 482.00M | 535.00M |
| Cash & Equivalents | 319.00M | 316.00M | 778.18M | 1.10B | 858.00M | 1.06B | 924.00M | 863.00M | 692.00M |
| Operating Cash Flow | 36.00M | (300.00M) | (4.00M) | 353.00M | (193.00M) | 151.00M | 289.41M | 309.87M | 372.72M |
| Free Cash Flow | 7.00M | (353.00M) | (9.00M) | 319.00M | (197.00M) | 144.00M | 250.25M | 264.70M | 340.67M |
| FCF per Share | 0.05 | -2.57 | -0.06 | 2.19 | -1.34 | 0.99 | 1.72 | 1.84 | 2.37 |
| Book Value | (348.00M) | (191.00M) | 51.28M | 203.00M | 82.00M | 209.00M | 66.00M | (203.00M) | (295.00M) |
| Cash & ST Investments | 320.00M | 410.00M | 897.83M | 1.10B | 858.00M | 1.06B | 924.00M | 863.00M | 692.00M |
| ROC Equity | N/A | N/A | -0.86 | 1.01 | -1.80 | 0.64 | 3.98 | N/A | N/A |